CLDI - Calidi Biotherapeutics, Inc.

Day 1m 10m 60m PreMarket Market AfterHours Gap
1.59 0.13 (8.18%) --- --- 0.01 (0.58%) 0.08 (5.05%) -0.01 (-0.6%) 0.06 (3.61%) 0.06 (3.61%)

Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.

Category: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Market Period: Closed

Earnings & Ratios

Basic EPS:
-1.99
Diluted EPS:
-1.99
Basic P/E:
-0.8643
Diluted P/E:
-0.8643
RSI(14) 1m:
100.0
VWAP:
1.72
RVol:

Events

Period Kind Movement Occurred At

Related News